InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor Mesutoclax for Myelodysplastic Syndromes in China
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor mesutoclax (ICP-248) in combination with azacitidine for the treatment of myeloid malignancies, including but not limited to myelodysplastic syndromes (MDS).
Mesutoclax is an important global asset of InnoCare in the field of hematology. This approval marks the Company will initiate the clinical trial for the fourth indication of our BCL2 inhibitor.
Mesutoclax is a novel, orally bioavailable BCL2 selective inhibitor. BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development of various hematologic malignancies. Mesutoclax exerts anti-tumor activity by selectively inhibiting BCL2 and restoring the normal apoptosis process in cancer cells.
Myelodysplastic syndrome (MDS) is a group of heterogeneous clonal myeloid diseases characterized by the abnormal proliferation of hematopoietic stem cells, recurrent genetic abnormalities, myelodysplasia, ineffective hematopoiesis, peripheral-blood cytopenia, and a high risk of progression to acute myeloid leukemia (AML). The annual incidence of myelodysplastic syndromes is about 4 cases/100,000 people/year (reaching 40–50/100,000 in patients aged ≥ 70 years).
Mesutoclax has been granted Breakthrough Therapy Designation (BTD) by the CDE for the treatment of BTKi-treated relapsed or refractory mantle cell lymphoma (R/R MCL). This marks the first BCL2 inhibitor to receive BTD recognition in China. The Company is accelerating patient enrollment of a Phase III registrational trial of mesutoclax in combination with orelabrutinib as a first line therapy for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), as well as a clinical trial of mesutoclax for the treatment of AML.
Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, 'Mesutoclax is an important global asset of our company in the field of hematology. We are delighted to receive approval to initiate the clinical trial for the fourth indication of our BCL2 inhibitor. We will accelerate the clinical development of mesutoclax across multiple indications in China and globally to bring benefits to patients as early as possible.'
About InnoCare
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.
InnoCare Forward-looking Statements
This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
26 minutes ago
- Business Wire
Project Management: A Fast-Growing Profession with High Demand and Competitive Salaries
LONDON--(BUSINESS WIRE)--In today's dynamic and complex business landscape, project management has emerged as one of the fastest-growing and most crucial professions. Whether it's orchestrating major infrastructure projects, managing a music festival or spearheading climate action initiatives. Project managers are at the heart of delivering successful outcomes across virtually every sector. In today's dynamic and complex business landscape, project management has emerged as one of the fastest-growing and financially rewarding professions. Share New research and data from the Association for Project Management (APM) underscores the growing significance and appeal of the profession. As of 2024, the average salary for a project manager in the UK stands at £52,500—an impressive increase from £47,500 in 2023. Sectors with the highest paying average project management salaries: Energy and Utilities - £62,500 Legal - £62,500 Consultancy - £62,500 Construction - £57,500 Financial Services - £57,500 Defence - £57,500 IT - £57,500 Professional Services - £57,500 Space industry - £52,500 The financially rewarding salary highlights the value placed on skilled project professionals and the return on investment for those who pursue a career in the field. The demand for project managers is not just reflected in salary data. APM's latest findings show a significant increase in employment within the sector. The number of full-time equivalent (FTE) project professionals in the UK has grown from 2.13 million in 2019 to approximately 2.32 million in 2024. This upward trend signals not only the expanding scope of project-based work but also the widening recognition of project management as a core capability within both private and public sector organisations. This boom in employment is mirrored by the profession's substantial contribution to the UK economy. Project management activities now generate an estimated £186.8 billion in Gross Value Added (GVA) annually. Such figures illustrate the pivotal role project professionals play in driving productivity, managing change, and ensuring strategic objectives are delivered on time and within budget. How to become a Project Manager: There is more than one route to becoming a project management professional. Entry routes include formal academic qualifications, professional certifications (such as qualifications offered by APM) and on the job training. Apprenticeships offer on-the-job learning and development so you can 'earn while you learn'. Many major organisations in the UK now run a project management apprenticeship programme. You don't need a degree to get into project management, as with the right experience, skills, qualifications, and commitment to professional development, there are many entry level jobs available such as assistant project manager or project assistant. This accessibility, combined with clear career progression paths and strong salary potential, makes project management an attractive option for recent graduates, career changers, and experienced professionals alike. Robin Carter-Evans, the education outreach manager at APM says: 'For young people it's important for them to initially understand what project management actually is, and that it's a profession in its own right. Every project needs a project team to keep a close watch on plans, budgets, teams, quality of outputs and any issues that may cause a problem to the project. Without one, projects are likely to fail. Projects come in different shapes and sizes, and all have an impact on the world around us.' As well as attracting school leavers and new graduates into the profession, the sector is also keen to recruit professionals from across other industries who already possess many of the key skills needed for success. Robin Carter-Evans explains: 'For career changers, the skillset needed for project management, which includes communication, leadership, planning, organisation, risk management, problem-solving, time management, and stakeholder management, are very transferrable.' Project management as a profession is evolving in response to global trends. As businesses navigate digital disruption, climate challenges, and the demand for sustainable practices, the role of the project manager is becoming increasingly strategic. Today's project managers are expected to not only deliver projects efficiently but also to align them with broader business goals, stakeholder expectations, and long-term sustainability targets. As industries continue to evolve and rely increasingly on project-based work, the importance of capable and qualified project professionals will only continue to grow. For further information about a career in project management visit
Yahoo
40 minutes ago
- Yahoo
Zai Lab Announces Participation in Investor Conferences in June 2025
SHANGHAI & CAMBRIDGE, Mass., May 30, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in June 2025: Jefferies Global Healthcare ConferenceFireside Chat: Wednesday, June 4, 2025, 10:30 a.m. ESTWebcast Link: Location: New York, NY Goldman Sachs 46th Annual Healthcare ConferenceTime: Monday, June 9, 2025Location: Miami, FL Scotiabank Third Annual Healthcare Canadian Investor DayTime: Tuesday, June 17, 2025Location: Toronto, Canada A live webcast of the fireside chat will be available on the Investor Relations page of Zai Lab's website at and archived replay will be available for up to 90 days following the completion of the event. About Zai Lab Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide. For additional information about Zai Lab, please visit or follow us at View source version on Contacts For more information, please contact: Investor Relations: Christine Chiou / Lina Zhang+1 (917) 886-6929 / +86 136 8257 / Media: Shaun Maccoun / Xiaoyu Chen+1 (857) 270-8854 / +86 185 0015 / Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented new translational data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study demonstrates that botensilimab-based therapy induces a robust and persistent T cell immune response in microsatellite stable (MSS), or mismatch repair proficient (pMMR), metastatic colorectal cancer (mCRC)—a tumor type traditionally resistant to immunotherapy and representing approximately 85-95% of all colorectal cancers. T cells are key immune cells capable of recognizing and attacking cancer cells. Activating these typically 'cold' tumors and driving a strong T cell response suggests that botensilimab has the potential to overcome resistance and improve patient outcomes. The research was led by Dr. Gertjan Rasschaert of Leuven University Hospitals in collaboration with Agenus, KU Leuven, and Omniscope. This joint effort brings together global leaders in immuno-oncology and advanced immune profiling technologies. 'These data provide clinical evidence of botensilimab's unique ability to enhance T-cell priming, activation, and diversity—key mechanisms that help render 'cold,' poorly immunogenic MSS colorectal tumors visible to the immune system,' said Dr. Dhan Chand, PhD, Vice President of Research at Agenus. 'Our findings offer new insight into how patients with immunotherapy-resistant colorectal cancer are responding at the immune level and highlight botensilimab's potential to activate immune responses in tumors that have historically been unresponsive.' Data Highlights: Fast T cell priming and activation: T-cells begin activating within two weeks of starting botensilimab. Robustly expands and sustains T cell activity: Newly primed T cells persist and expand across treatment cycles, correlating with improved clinical responses. Immune activity detected before scans: Immune-profiling tests detect this activity even when standard imaging hasn't yet caught a response. Blood signals predict benefit: A quick blood draw can reveal early immune markers that help doctors identify who is most likely to respond and live longer. 'We're seeing — at the immune level — how botensilimab can help the body recognize and attack pMMR colorectal cancer, a form of the disease that has historically resisted immunotherapy and represents the vast majority of colorectal cancer cases,' said Dr. Steven O'Day, Chief Medical Officer at Agenus. 'By activating T cells and making these typically 'cold' tumors visible to the immune system, botensilimab is showing real promise in overcoming resistance and opening the door to better outcomes for patients who previously had limited options.' Presentation Details: The presentation will be available on the publications section of the Agenus website at on the date of the poster session. Presentation Title: Monitoring botensilimab and balstilimab induced T cell dynamics in refractory mismatch repair proficient metastatic colorectal cancer. Presenting Author: Poster Session: Gastrointestinal Cancer—Colorectal and Anal Session Date and Time: May 31 st, 2025; 9:00 AM-12:00 PM CDT Abstract Number: 3527 Poster Number: 196 About Botensilimab (BOT) Botensilimab is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to 'cold' tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses. Approximately 1,100 patients have been treated with botensilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus' investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit About Balstilimab (BAL) Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types. About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," 'establish,' 'potential,' 'superiority,' 'best in class,' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2024, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
